ATOSSA GENETICS WKN: A2JJ99 ISIN: US04962H5063 Forum: Aktien Thema: Hauptdiskussion

Hier ballert es morgen!!!!

Gerüchte? Was den für Gerüchte 🤔😊

Irgendwie gehen da gerade Gerüchte herum

Irgendwie ist alles am steigen

Was geht ab?

Die ocugen aktie ist am steigen wie sieht es hier aus??

wie schautz aus mit dem covid spray?

🚀🚀🚀

https://www.investorsobserver.com/news/stock-update/should-you-hold-atossa-therapeutics-inc-atos-stock-friday-morning

Der Link funktioniert nicht....

https://www.investorsobserver.com/news/stock-update/atossa-therapeutics-atos-stock-is-higher-after-unveiling-global-rd-lab

Auszug aus einem YF-Beitrag: „…… 3. On 01/22, these was a S3 filled: "This Registration Statement registers 10,500,000 shares of common stock of the Registrant issuable upon the exercise of warrants (the “warrants”) acquired by the selling stockholders in a December 17, 2020 private placement transaction (the “private placement”). ". BTW, their exercise price was $1.00 per share. Then, on 01/25, ATOS anno. that "Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021", then PPS went up from $1.87 to a high of $3.77 in Pre-MKT on 01/26. Then on 01/29, ATOS anno. that "Atossa Therapeutics Receives $21 Million from Recent Exercises of Outstanding Warrants". 4. Based on the last S3 and my other past exp with BIO Stocks, today's S3 tells me the following: a. The positive P2 Data of Endoxifen is imminent (should come out within a week), and the 10 Funds are just setting up to be able to cash in their Warrants too; b. Compared with the quality of the news on 01/25, the P2 Data should be a much bigger news for sure. So, it would not surprise me if the PPS breaks the 53 week high of $5.08 on that day ( espe. if the news gets released in Pre-MKT or Post MKT, i.e., shorts will be covering like crazy); 5. Like what happened back in Jan., there might be a second good news after the P2 Data too within in a week or so. On 02/02, ATOS released that "Atossa Therapeutics’ Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted Early", then PPS reached a high of $4.90 in Pre-MKT on 02/04 (closed at $2.37 on 02/01). Based on all my DD since mid of 12/2020, I believe that there could be a second/follow-up good news right before 05/14/2021 (the annual SH Holder meeting). My guess is that it might be a potential BO or start of P2 of Endoxiofen for BMD.“

Hier knallt es endlich!!! 🎉🎉🎉

Was bedeutet Form S-3?

Versteh nur Bahnhof

Newsletter